Cytokines regulate the affinity of soluble CD44 for hyaluronan  by Cichy, Joanna & Puré, Ellen
Cytokines regulate the a⁄nity of soluble CD44 for hyaluronan
Joanna Cichya;b;, Ellen Pure¤b;c
aFaculty of Biotechnology, Jagiellonian University, Ul. Gronostajowa 7, 30-387 Krako¤w, Poland
bWistar Institute, Philadelphia, PA 19104, USA
cLudwig Institute of Cancer Research, New York, NY 10158, USA
Received 24 October 2003; accepted 11 November 2003
First published online 27 November 2003
Edited by Masayuki Miyasaka
Abstract CD44, a receptor for the extracellular matrix gly-
cosaminoglycan hyaluronan, has been implicated in many adhe-
sion-dependent cellular processes including tumor growth and
metastasis. Soluble CD44 has been identi¢ed in the serum of
normal individuals. Furthermore, tumor progression is often as-
sociated with marked increases in plasma levels of soluble
CD44. Release of soluble CD44 by proteolytic cleavage (shed-
ding) of membrane-anchored CD44 is likely to alter cellular
responses to the environment due to modi¢cation of the cell
surface and the potential for soluble CD44 to in£uence CD44-
mediated hyaluronan binding to cell surfaces. Cellular activation
is typically required to induce hyaluronan binding to cell surface
CD44 but the a⁄nity of endogenous soluble CD44 for hyalur-
onan remains unknown. In this study, we demonstrate that on-
costatin M and transforming growth factor L1 (TGF-L1) which
stimulate hyaluronan binding to HTB58 lung epithelial-derived
tumor cells, also induce the release of soluble CD44. Interest-
ingly, soluble CD44 released by oncostatin M-treated cells re-
tained the ligand-binding properties of the membrane-anchored
receptor. In contrast, soluble CD44 released from TGF-L1-
treated HTB58 cells di¡ered in its hyaluronan-binding capacity
from cell surface CD44 expressed on TGF-L1-stimulated cells.
These data indicate that the mechanisms that regulate the gen-
eration of soluble CD44 may also govern the binding of the
released receptor to hyaluronan and therefore determine the
impact on CD44-dependent physiologic and pathologic process-
es.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Cleavage of membrane-anchored proteins (shedding) is as-
sociated with modi¢cation of cell surfaces and the release of
biologically active molecules. As a result, proteolytic release of
membrane proteins represents an important mechanism for
altering cellular responses to the environment. Accumulating
evidence suggests that adhesion molecule expression and ac-
tivity can be regulated through shedding [1,2]. The in£amma-
tory response, and the formation of tumor metastasis, in-
volves interactions between cell adhesion molecules on
leukocytes and tumor cells with endothelium and subendothe-
lial parenchymal cells and matrix at sites of in£ammation and
tumor dissemination, respectively. Regulated proteolysis has
been proposed as a mechanism to rapidly down-regulate the
levels of adhesion molecules and thereby disrupt cell^cell and
cell^matrix interactions. For example, L-selectin is rapidly
down-regulated following activation of leukocytes resulting
in alterations in the tra⁄cking patterns of activated compared
to naive leukocytes [1,2]. In addition, soluble adhesion recep-
tors may exhibit biologic activity. For example, soluble syn-
decan-1 ectodomain, a heparan sulfate proteoglycan shed
from cell surfaces into wound £uids, is a potent inhibitor of
heparin-mediated ¢broblast growth factor 2 mitogenicity [3].
CD44 is a widely distributed cell surface glycoprotein im-
plicated in cell^cell adhesion and cell^matrix interaction
largely through its a⁄nity for hyaluronan (HA), a ubiquitous
extracellular matrix glycosaminoglycan [4^6]. CD44 expres-
sion and HA binding has been linked to the metastatic poten-
tial of tumors [7] as well as autoimmunity and in£ammation
[8,9]. CD44 derives from a single gene, but is expressed as
multiple isoforms ranging in molecular weight from 80 to
250 kDa. This structural diversity arises from utilization of
alternatively spliced mRNA templates, which can be further
modi¢ed posttranslationally by glycosylation or the attach-
ment of glycosaminoglycans. The most common form of
CD44 (CD44H) has an apparent molecular weight of 80^
100 kDa and does not contain di¡erentially spliced exons
[10]. This structural diversity of CD44 translates into a pleio-
tropic adhesion molecule capable of interacting with multiple
molecules in addition to HA, including growth factors, cyto-
kines, and extracellular matrix proteins such as ¢bronectin
and collagen. Importantly, the ability of CD44 on the vast
majority of cell types to bind HA with high a⁄nity is not
constitutive, rather cellular activation is required to induce
HA binding. However, HA-binding ability of cell surface
CD44 appears to be required to exert biological e¡ects on
HA-related cellular functions, including growth and metasta-
sis of some tumors [11]. A variety of mechanisms have been
implicated in the transition from inactive to active forms of
CD44, including variant exon usage, receptor oligomerization,
glycosylation and sulfation. The ability of cell surface CD44
to bind HA can be modulated by soluble factors, including
cytokines [12,13]. In addition, an excess of soluble CD44
(sCD44) may compete with membrane-anchored CD44 for
HA binding, thus providing another mechanism for modula-
tion of cell surface CD44-mediated HA interactions.
Signi¢cant levels of sCD44 have been detected in serum and
lymph from a variety of species. Increased serum levels of
CD44 have been documented in association with malignancy
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and with immune activation whereas immunode¢ciency is cor-
related with low concentrations of sCD44 [14], indicating that
immunological and malignant activity may promote the re-
lease of sCD44. The generation of sCD44 is believed to in-
volve mainly proteolytic cleavage (shedding) of cell surface,
and possibly di¡erential splicing of CD44 since a CD44 tran-
script devoid of the transmembrane and cytoplasmic domains,
and thus encoding a soluble truncated CD44 receptor, has
been identi¢ed in mouse fetal myoblasts CD44 (reviewed in
[15]). Although correlation between elevated plasma levels of
CD44 and malignant diseases has generated interest in CD44
as a potential biomarker for tumor malignancy, the role of
sCD44 remains to be elucidated. To gain insight into the
biology of sCD44 it is important to determine its HA-binding
ability. Previous reports demonstrated that a chimeric protein
consisting of the extracellular domain of CD44 and IgG Fc
can block binding of cell surface CD44 to HA. However, little
is known about the relative HA-binding capacity of native
sCD44 released from cells compared to cell surface CD44.
In this study we demonstrate that oncostatin M (OSM) and
transforming growth factor L1 (TGF-L1) induce the release of
sCD44 from lung epithelial-derived tumor cells and that
sCD44 released by cytokines from these cells either retains
the ligand-binding properties of the membrane-anchored re-
ceptor or di¡ers in its HA-binding capacity from cell surface
CD44 depending on the stimulant, suggesting that sCD44
may di¡erentially contribute to CD44-mediated processes.
2. Materials and methods
2.1. Materials
Human recombinant OSM and human recombinant TGF-L1 were
purchased from RpD Systems (Minneapolis, MN, USA). The follow-
ing anti-human CD44 monoclonal antibodies (mAbs) were used [10]:
5F12 that blocks HA binding (a generous gift of Dr. B.F. Haynes,
Duke University Medical Center, Durham, NC, USA), Hermes III
(American Tissue Type Collection (ATCC), Rockville, MD, USA),
and G44-26 (PharMingen, San Diego, CA, USA). Puri¢ed HA from
rooster comb and hyaluronidase from Streptomyces were purchased
from Sigma (St. Louis, MO, USA). Fluorescein-conjugated rooster
comb HA (FITC-HA) was prepared as described [16]. FITC-labeled
anti-human CD44 antibodies and phycoerythrin (PE)-labeled strepta-
vidin were purchased from PharMingen. Biotinylated hyaluronic acid-
binding protein was obtained from Seikagaku (Tokyo, Japan). Alka-
line phosphatase-conjugated anti-£uorescein antibodies were obtained
from Roche (Indianapolis, IN, USA). CD44-2-Rg vector [4] was a
generous gift of Dr. I. Stamenkovic (Harvard Medical School, Cam-
bridge, MA, USA). The bicinchoninic acid kit was purchased from
Pierce (Rockford, IL, USA), and enhanced chemiluminescence (ECL)
system from Amersham Pharmacia Biotech.
2.2. Cell culture
HTB58, a human lung squamous carcinoma cell line, was obtained
from ATCC. HTB58 cells were cultured in Eagle’s modi¢ed essential
medium supplemented with 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate, 50 Wg/ml gentamicin and 10% heat-inactivated fetal
bovine serum. Equal numbers of cells were plated, grown to con£u-
ence and where indicated treated with 50 ng/ml OSM and/or 10 ng/ml
TGF-L1 for 48 h. Treatment with OSM and/or TGF-L1 generally did
not change cell number by more than 5%. Optimal doses and kinetics
determined in preliminary experiments were used in this study.
2.3. Biosynthetic and sulfate labeling, immunoprecipitation and
£uorography
Cells were incubated for 48 h in methionine-free medium containing
200 WCi/ml [35S]methionine/cysteine (Trans 35S-label) (ICN). Condi-
tioned media were collected and centrifuged at 300Ug for 10 min
followed by 600Ug for 15 min to remove cells and cellular debris.
Conditioned media were normalized based on cell number, precleared
with pre-immune serum and then precipitated with G44-26 followed
by protein A/G plus agarose. Immune complexes were washed sequen-
tially with high salt (0.6 M NaCl, 125 mM KPO4 pH 7.4, 0.02%
NaN3), mixed detergent bu¡er (0.05% NP-40, 0.1% sodium dodecyl
sulfate (SDS), 0.3 M NaCl, 10 mM Tris pH 8.6), and phosphate-
bu¡ered saline (PBS). CD44 was then released by boiling in Laemmli
sample bu¡er and resolved by SDS^8% polyacrylamide gel electro-
phoresis (PAGE) under non-reducing conditions. Bands were detected
by £uorography.
2.4. Flow cytometry
Cells were harvested using 0.2% EDTA, stained for HA binding
using HA-FITC, and analyzed on a FACScan. Non-speci¢c reactivity
was based on staining with HA-FITC in the presence of blocking anti-
CD44 mAb 5F12. To determine the level of HA associated with cell
surface, HTB58 cells were stained with biotinylated HA-binding pro-
tein (bPG) followed by PE-conjugated streptavidin. Speci¢city was
veri¢ed by pretreating the cells with 20 U/ml hyaluronidase at 37‡C
for 2 h followed by staining with bPG and PE-conjugated strepta-
vidin.
2.5. CD44-speci¢c enzyme-linked immunosorbent assay (ELISA)
sCD44 was quanti¢ed by ELISA. Plates (Microlite1 2, Dynex,
Chantilly, VA, USA) were coated with 2 Wg/ml of mAb Hermes III
in Tris-bu¡ered saline (50 mM Tris^HCl pH 9.5, 150 mM NaCl). The
plates were then washed with PBS containing 0.05% Tween 20, and
non-speci¢c protein-binding sites were blocked with 3% bovine serum
albumin (BSA) in PBS. Standards and samples were added and incu-
bated at room temperature for 2 h. A⁄nity-puri¢ed CD44-immuno-
globulin fusion protein (CD44-2-Rg) containing the complete extra-
cellular domain of CD44H was used as a standard. After washing,
FITC-labeled anti-CD44 G44-26 mAb was added to the wells and
incubated at 37‡C for 30 min. Bound antibody was detected by in-
cubation with alkaline phosphatase-conjugated anti-FITC mAb and
developed with p-nitrophenyl phosphate. Absorbances were then read
at 405 nm with a plate reader, and after subtraction of background
values, the readings were used to construct a standard curve.
2.6. ELISA for HA binding
To quantify CD44 capable of binding HA, plates were coated with
Hermes III mAb, washed and incubated with standards and samples
as described above. In some instances, conditioned media were con-
centrated on Centricon YM-10 (Millipore, Bedford, MA, USA), or
subjected to immunoprecipitation with Sepharose-conjugated anti-
CD44 Hermes III mAb. CD44 was then eluted from the beads with
100 mM glycine, pH 2.5, and after neutralization to pH 7.5 with Tris^
HCl, CD44 was used for ELISA. FITC-labeled HA was added to the
wells and incubated at 37‡C for 30 min followed by incubation with
alkaline phosphatase-conjugated anti-FITC mAb and p-nitrophenyl
phosphate.
The level of sCD44 occupied by endogenous HA was examined as
follows: streptavidin-coated plates (Pierce) were coated with 2.5 Wg/ml
of bPG or biotinylated anti-CD3 Ab as negative control, in Tris-bu¡-
ered saline. After blocking of non-speci¢c protein-binding sites with
3% BSA, conditioned media were added and incubated at room tem-
perature for 2 h to capture HA. CD44 associated with HA was then
detected by FITC-labeled anti-CD44 G44-26 mAb. Speci¢c capture of
CD44^HA complexes from the conditioned media was calculated by
subtracting non-speci¢c binding to CD3 Ab. In order to quantify
sCD44 associated with HA, conditioned media were preincubated
on plates coated with bPG. Two rounds of incubation on bPG-coated
plates were su⁄cient to deplete the conditioned media with CD44^HA
complexes. Depleted media were then assayed in parallel with full
(undepleted) conditioned media by CD44-speci¢c ELISA.
2.7. Detection of HA released by cells
In order to determine the HA content in the media we developed a
modi¢ed ELISA based on competitive binding of endogenous and
FITC-labeled exogenous HA to microwell-bound bPG. The condi-
tioned media from cells incubated for 48 h were added to ELISA
plates (Pierce) coated with bPG and blocked with 3% BSA. Condi-
tioned media were incubated at room temperature for 2 h to capture
endogenous HA. Unlabeled puri¢ed HA was used as a standard. Un-
saturated bPG sites were then detected by incubation with FITC-HA
at 37‡C for 30 min followed by incubation with alkaline phosphatase-
conjugated anti-FITC mAb and p-nitrophenyl phosphate.
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3. Results
3.1. OSM and TGF-L1 increase the release of CD44 from
tumor cells
Most of the known e¡ects of CD44 on cell adhesion and
migration are intimately associated with its capacity to pro-
mote cell attachment to HA. We previously demonstrated that
OSM and TGF-L1 induce transition of transmembrane CD44
from its low to its high a⁄nity state in lung-derived tumor
HTB58 cells [13], but the e¡ects of cytokines on the release of
sCD44 and the HA-binding capacity of sCD44 have not been
investigated. To determine if cytokines regulate shedding of
CD44, release of CD44 from untreated and cytokine-stimu-
lated HTB58 cells was investigated. HTB58 cells were found
to spontaneously release CD44 into the conditioned media
(Fig. 1A). OSM and TGF-L1 induced comparable, statistically
signi¢cant increases in levels of sCD44 as determined by
ELISA (Fig. 1A). Flow cytometry analysis con¢rmed that
the release of sCD44 into the culture media was associated
with 20^30% reduction in cell surface CD44 in HTB58 cells
treated with OSM alone or a combination of OSM and TGF-
L1 as previously reported [13]. On average, the reduction in
membrane-bound receptor following TGF-L1 treatment was
less pronounced compared to OSM-treated cells. In fact, the
e¡ect of TGF-L1 was variable, ranging from 0% to 20% re-
duction in cell surface CD44 ([13], and data not shown).
These di¡erences may re£ect variability in CD44 cell surface
staining as a result of accumulation of pericellular matrix in
TGF-L1-treated cells.
Immunoprecipitation of CD44 from 48-h conditioned me-
dia from metabolically labeled HTB58 cells revealed the re-
lease of three major species of sCD44 of approximately 180
kDa, 90 kDa and 60 kDa (Fig. 1B). No di¡erence in the
apparent molecular mass of sCD44 was observed between
control and cytokine-treated cells.
Importantly, a di¡erent pro¢le of CD44 species was de-
tected in conditioned media of [35S]sulfate-labeled HTB58
cells subjected to immunoprecipitation using anti-CD44
mAb. Speci¢cally, although large sulfated species which did
not penetrate the gel were recovered from conditioned media
of untreated and cytokine-treated cells, only in conditioned
media from cells treated with either OSM or OSM plus
TGF-L1 were additional sulfated species of 150^210 kDa de-
tected (Fig. 1C).
3.2. Cytokines regulate the a⁄nity of sCD44 for HA
To determine if sCD44 released from HTB58 cells retains
function we used an ELISA speci¢c for CD44 capable of
binding HA. Total CD44 from conditioned media of control
or cytokine-treated cells was ¢rst quanti¢ed by CD44-speci¢c
ELISA. Comparable amounts of CD44 were then captured on
anti-CD44 Hermes III-coated ELISA plates. Bound receptor
was then incubated with FITC-labeled HA and the bound
ligand was detected using alkaline phosphatase-conjugated
anti-FITC mAb. Only a small proportion of the total sponta-
neously released CD44 that accumulated over the 48-h culture
period in HTB58 cell conditioned media exhibited a⁄nity for
HA. Interestingly, although the sCD44 released in response to
treatment with OSM exhibited a signi¢cantly higher capacity
to bind HA compared to spontaneously released CD44, the
sCD44 released in response to TGF-L1 did not (Fig. 2).
sCD44 released from OSM+TGF-L1-treated cells bound HA
Fig. 1. OSM and TGF-L1 induce the release of CD44 from HTB58
cells. Cells were treated for 48 h with 50 ng/ml OSM and/or 10 ng/
ml TGF-L1. Levels of released CD44 were then determined in con-
ditioned media by ELISA (A). The data are shown as the mean of
triplicate wells from four experiments. The di¡erence between con-
trol and cytokine-treated cells was statistically signi¢cant as deter-
mined by Student’s t-test (P6 0.05). CD44 from [35S]methionine-la-
beled (B) or [35S]sulfate-labeled (C) 48-h conditioned media of
untreated or OSM- and TGF-L1-treated cells was immunoprecipi-
tated with anti-CD44 mAb followed by protein A/G plus agarose.
Immune complexes were resolved by SDS^8% PAGE under non-re-
ducing conditions followed by £uorography. Molecular weight
markers in kDa are indicated.
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to a much lesser extent than from cells stimulated with OSM
alone. These data indicate that although OSM and TGF-L1
both induce CD44-mediated HA binding to HTB58 cells and
the release of comparable levels of sCD44 (Figs. 2A and 1A,
respectively), the sCD44 released exhibits markedly di¡erent
capacities to bind HA depending on the stimuli. The potential
for dichotomy between the a⁄nity of cell surface CD44 and
sCD44 in cytokine-stimulated HTB58 cells for HA is further
emphasized by the fact that a combination of OSM and TGF-
L1 was most potent in inducing the release of sCD44 and
inducing HA binding to cell surface CD44 (Fig. 2A and
[13], and Fig. 1A, respectively), but induced marginal binding
of the sCD44 to HA (Fig. 2B).
We have previously demonstrated that in HTB58 cells HA-
binding function of cell surface CD44 is regulated by receptor
sulfation induced in response to OSM and OSM plus TGF-L1
[13]. Since sCD44 generated in HTB58 cells was found to be
sulfated (Fig. 1C) it raised the question of whether sulfation
of sCD44 regulates its interactions with HA. As demonstrated
in Fig. 2B, treatment of cells with NaClO3 reduced the ability
of sCD44 generated in response to OSM, TGF-L1 and OSM
plus TGF-L1 to interact with HA by 71%, 44% and 93%
respectively, indicating that sulfation of sCD44 markedly en-
hances its HA-binding capacity. HA binding to sCD44 spon-
taneously released from cells treated with chlorate was below
the level of detection of the ELISA. Since OSM- and TGF-L1-
generated sCD44 species di¡ered in sulfation pattern (Fig.
1C), these di¡erences may at least partially account for the
observed di¡erences in HA binding between sCD44 released
under various conditions.
Fig. 2. Comparison of HA binding by cell surface CD44 and
sCD44. Cells were cultured in the absence or presence of 40 mM
sodium chlorate for 48 h. Cell were than treated for an additional
48 h with 40 mM sodium chlorate, 50 ng/ml OSM and/or 10 ng/ml
TGF-L1 as indicated. CD44-mediated HA binding in HTB58 cells
was determined by £ow cytometry after exposure of cells to FITC-
HA. Speci¢c binding was calculated by subtracting non-speci¢c
binding in the presence of blocking HA-binding anti-CD44 5F12
mAb. Fluorescence intensity is shown from one representative ex-
periment out of three independent experiments (A). Conditioned
media were concentrated and subjected to CD44-speci¢c ELISA to
estimate the amount of CD44. Aliquots of media containing compa-
rable amounts of CD44 were then analyzed using functional ELISA
speci¢c for CD44 capable of binding HA. The data are shown as
the mean of triplicate wells from three experiments (B). The di¡er-
ence between control and cytokine-treated cells depicted in A was
statistically signi¢cant as determined by Student’s t-test (P6 0.05).
In B, the di¡erence between control and cytokine-treated cells was
statistically signi¢cant for OSM- and OSM+TGF-L1-treated cells.
The e¡ect of chlorate treatment shown in B was statistically signi¢-
cant.
Table 1
Cytokines increase HA levels in HTB58 cells
Reactivity of bPG with the cell surface (MFI) Level of HA in conditioned medium (Wg/ml per 106 cells)
Control 260 0.46
OSM 600 0.48
TGF 350 0.22
OSM+TGF 797 0.56
Cells were cultured for 48 h with 50 ng/ml OSM and/or 10 ng/ml TGF-L1. Surface levels of HA were analyzed by £ow cytometry after staining
with bPG followed by PE-conjugated streptavidin. Cells treated with hyaluronidase prior to staining with bPG+PE-conjugated streptavidin
were used as a negative control. Results are expressed as an average of two independent experiments (left column; MFI, mean £uorescence in-
tensity). Conditioned media from cells incubated for 48 h were added to ELISA plates coated with bPG. Unsaturated bPG-binding sites were
then detected by incubation with FITC-labeled HA followed by alkaline phosphatase-conjugated anti-FITC Ab. The data represent HA concen-
tration in conditioned media after subtracting values obtained for culture media and are shown as the mean of quadruplicate wells from two
experiments (right column).
Fig. 3. sCD44 is associated with HA in cytokine-treated HTB58
cells. Conditioned media from cells incubated for 48 h were split
into two groups. The ¢rst group was subjected to CD44-speci¢c
ELISA. The second group was added to ELISA plates coated with
bPG to capture sCD44 associated with HA. After two rounds of in-
cubation with microwell-bound bPG, the conditioned media de-
pleted with CD44^HA complexes were subjected to CD44-speci¢c
ELISA. The percentage of sCD44 associated with HA is shown as
the mean of duplicate wells from two experiments.
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3.3. TGF-L1 induces the release of CD44 complexed to HA
HTB58 cells synthesize HA (Table 1), raising the possibility
that the decreased capacity of sCD44 released by TGF-L1 and
a combination of TGF-L1 and OSM to bind HA may be due
to occupation of the released receptor with endogenous HA.
To address this possibility, HA from conditioned media of
untreated and cytokine-stimulated HTB58 cells was captured
on ELISA plates coated with HA-binding protein (bPG).
CD44 associated with HA was then detected by anti-CD44
mAb. This assay revealed that the CD44 released from TGF-
L1- or TGF-L1+OSM-treated cells is associated with HA
while CD44 released spontaneously and from OSM-treated
cells was predominantly free of HA. To quantify the propor-
tion of the sCD44 occupied by endogenous HA, HA-as-
sociated CD44 was depleted from conditioned media by in-
cubation with microwell-bound bPG. The depletion was
considered to be complete if sCD44 was no longer able to
bind to microwell-bound bPG. The level of free CD44 was
then determined by CD44-speci¢c ELISA. As demonstrated in
Fig. 3, only 1% of sCD44 was found to be complexed with
endogenous HA in supernatants from untreated cells, whereas
approximately 30% of total sCD44 was associated with en-
dogenous HA in TGF-L1- and OSM+TGF-L1-treated cells
and 10% in OSM-stimulated cells. To determine if association
of CD44 with HA resulted from higher expression of HA in
TGF-L1-treated cells, we examined the levels of HA on the
cell surface where HA is synthesized, as well as in conditioned
media of HTB58 cells. Flow cytometry revealed that treat-
ment of HTB58 cells with TGF-L1 slightly increased the
bPG binding to the cell surface (V35%), whereas stimulation
with OSM plus TGF-L1 or OSM alone resulted in profound
increases in HA surface levels (207% and 131%, respectively)
(Table 1). Similarly, the level of HA released into the condi-
tioned media was highest in OSM plus TGF-L1- and OSM-
treated cells (Table 1). Thus, formation of complexes between
sCD44 and endogenous HA appears to be preferentially in-
duced by TGF-L1 and does not correlate with levels of en-
dogenous HA detected by the bPG staining. However, it
should be noted that the lower levels of HA detected in the
conditioned media from TGF-L1-stimulated cells might result
from partial depletion of HA as the result of formation of
complexes with sCD44.
4. Discussion
A wide variety of cells have been reported to shed CD44,
including leukocytes and epithelial cells. Some cells release
basal levels of sCD44 constitutively. In addition, the release
of sCD44 can be induced experimentally by phorbol 12-myr-
istate 13-acetate and ionomycin in vitro [9,17]. Although the
physiological inducers of CD44 release are largely unknown,
crosslinking of CD44 by speci¢c antibodies leads to CD44
release [18], which raises the possibility that generation of
sCD44 is ligand-inducible. The regulated proteolysis of this
receptor may play a role in metastasis-associated cell migration
since increases in the levels of sCD44 are found during tumor
progression [14,19]. This possibility is also consistent with the
¢nding that CD44 cleavage is induced by Ras, an oncoprotein
involved in cell motility and migration [20]. Interestingly, sta-
ble transfection of murine mammary carcinoma cells with
sCD44 led to inhibition of tumor cell proliferation. These
changes in tumor cell growth were dependent on the ability
of sCD44 to bind HA, indicating that sCD44, which has af-
¢nity for HA, can act as a competitive inhibitor of HA^pro-
tein interactions [21]. However, so far nothing is known about
the mechanisms regulating the a⁄nity of sCD44 for HA.
We previously demonstrated that in HTB58 cells, HA bind-
ing to the cell surface can be regulated by OSM and TGF-L1,
cytokines that also have the potential to regulate tumorigen-
esis [13]. The data presented in this paper demonstrate the
ability of both OSM and TGF-L1 to increase the release of
CD44 from HTB58 cells. This observation provided a unique
opportunity to study shedding of CD44 in the context of
di¡erential HA binding. There are several major ¢ndings in
this study: (i) shedding of CD44 appeared to correlate with an
increased a⁄nity of cell surface CD44 to HA, (ii) cytokines
regulate HA-binding activity of both the transmembrane and
soluble forms of CD44, (iii) di¡erences in HA-binding ca-
pacity of sCD44 are stimulant-dependent, (iv) either mem-
brane-anchored or soluble CD44 can associate with HA. Tak-
en together these results indicate that epithelial cell CD44^HA
interactions are regulated by two mechanisms: cytokine-medi-
ated modulation of CD44 adhesion function and release of
CD44. To our knowledge this is the ¢rst demonstration that
shedding of CD44 triggered by physiological stimuli can result
in generation of sCD44 which di¡ers in HA binding. This is
an important ¢nding since sCD44 is generally assumed to
simply antagonize the e¡ect of membrane CD44. Future stud-
ies, however, will be required to fully understand the biolog-
ical e¡ects of sCD44 with di¡erent a⁄nity for HA on HA-
related cellular functions. Based on the ¢ndings presented in
this study it can be proposed that sCD44 serves a dual func-
tion: as an antagonist of cell surface CD44 or as a decoy
receptor or matrix component. Since sCD44 released by
OSM is able to bind HA, the physiological e¡ects of the
OSM-generated sCD44 may contradict that of its cell surface
counterpart through competition for the same ligand. In con-
trast, sCD44 released by TGF-L1 is unlikely to compete e⁄-
ciently with membrane-bound CD44 for HA. Instead, TGF-
L1 may alter the repertoire of CD44 anchored to the cell
surface through release of sCD44 at least partially associated
with HA and possibly other matrix components into the
extracellular milieu.
It has been demonstrated that the transmembrane form of
CD44 plays a role in the assembly of HA-rich pericellular
matrices [22,23]. Our data demonstrate that CD44 is also
associated with HA after it is proteolytically cleaved from
the cell surface and that the level of sCD44^HA complexes
is di¡erentially regulated by various cytokines. There are at
least two, not mutually exclusive, scenarios by which sCD44^
HA complexes may be generated. Transmembrane CD44 may
be ¢rst proteolytically cleaved and released from the cell sur-
face and then establish physical associations with HA subse-
quent to release of the receptor from the cell surface. Alter-
natively, transmembrane CD44 may play a seminal role in the
formation of matrix at the cell surface where subsequent pro-
teolysis of the membrane-anchored CD44 would result in re-
lease of CD44 pre-assembled into complexes in association
with HA. The composition of the extracellular matrix and
its organization are the major determinants of environmental
signaling that controls cell fate under physiologic and patho-
logic conditions. Our studies indicate that CD44 released from
the cell surface may also be involved in assembly of the matrix
surrounding lung epithelial cells.
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